Remove Clinical Trials Remove DEA Remove History
article thumbnail

ASA offers solution to DOJ research block: Our comments on the DEA’s proposed rules

Americans for Safe Access

On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.

article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.

DEA 103
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Final Phase of MDMA Clinical Trials Shows Drug Is 90% Effective at Treating PTSD

SpeedWeed

A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The subjects had been experiencing PTSD symptoms for an average of 14 years, and 84 percent had a history of developmental trauma. Image via.

article thumbnail

DEA Faces Lawsuit For Denying End of Life Patients the Right to Try Psychedelics Therapy

Veriheal

Plant medicines and concoctions made from them have been utilized throughout the history of cultures around the world. In the last 100 years, many of the plant therapies that were embraced in history were outlawed by governments around the world and replaced by lab-made synthetic drugs we label medicine.

Therapy 63
article thumbnail

Bank of America Shuts Down Cannabis Research Facility Account

Cannabis Law Report

Bank of America (BoA) is reportedly terminating its banking relationship with Scottsdale Research Institute (SRI), a DEA-registered facility that carries out important marijuana research. So, given the history and credibility of the Institute, why did BoA terminate the 10-year banking relationship with SRI?

Banking 52
article thumbnail

MAPS Organization Granted $12.9 Million to Study Cannabis and PTSD •

SpeedWeed

MAPS Makes History. This will be the second clinical trial to give cannabis medicine or placebos to participating military veterans, and according to the Chief Science Officer of the MAPS Public Benefit Corporation, Berra Yazar-Klosinki, PhD, the first trial was a great success. “We

article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

This landmark approval is unique in that ketamine is well known to have hallucinogenic properties, as well as a long history as a party drug. Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Fortunately, this issue shouldn’t be a show-stopper. Potential IPOs within the next year.